August 17, 2017
Cosentyx Plateaus as Non-TNF Agents Prepare to Dominate in Psoriatic Arthritis
From: Specialty Pharma Time
By: Lauren Santye
Although there are a growing number of rheumatologists in the United States who report the use of Cosentyx to treat psoriatic arthritis (PsA), the increasing user base has failed to translate into overall increases in biologic share, according to market research company Spherix Global Insights. The plateau of Cosentyx is partially fueled by pipeline PsA agents, which offer patients more options for non-TNF treatments, including Orcenia, Xeljanz, and Taltz, according to a press release….(read more).